Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)

Condensed Consolidated Interim Financial Statements
For the three month and nine month periods ended 30 September 2025

INDEX **PAGE**

Report on review of condensed consolidated interim financial statements

To the shareholders of Dr. Sulaiman Al Habib Medical Services Group Company
(A Saudi Joint Stock Company)

Introduction

We have reviewed the accompanying condensed consolidated interim statement of financial position of Dr. Sulaiman Al Habib Medical Services Group Company (“the Company”) and its subsidiaries (collectively with the Company referred to as “the Group”) as at 30 September 2025, and the related condensed consolidated interim statements of profit or loss and comprehensive income for the three-month and nine-month periods ended 30 September 2025, and the related condensed consolidated interim statements of changes in equity and cash flows for the nine-month period then ended, and other explanatory notes. The Board of Directors are responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with International Accounting Standard 34, “Interim Financial Reporting” (“IAS 34”), as endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed consolidated interim financial statements based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, as endorsed in the Kingdom of Saudi Arabia. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing, as endorsed in the Kingdom of Saudi Arabia, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements are not prepared, in all material respects, in accordance with IAS 34, as endorsed in the Kingdom of Saudi Arabia.

PricewaterhouseCoopers

برايس وترهاوس كوبرز
محاسبون قانونيون
س.ت: ١٠١٠٣٧١٦٢٢
PRICEWATERHOUSECOOPERS
CERTIFIED PUBLIC ACCOUNTS
C.R.: 1010371622

Khalid A. Mahdhar
License Number 368

26 October 2025

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Condensed consolidated interim statement of financial position
As at 30 September 2025

	Notes	30 September 2025 ⃁ (Unaudited)	31 December 2024 ⃁ (Audited)
Assets			
Current assets			
Cash and cash equivalents		2,111,268,161	2,890,702,697
Accounts receivable		1,633,225,087	1,110,377,832
Prepayments and other assets		589,599,568	471,466,187
Inventories		1,070,421,352	846,880,231
Total current assets		**5,404,514,168**	**5,319,426,947**
Non-current assets			
Investments in associates and others		163,124,448	165,353,436
Investments in equity instruments – Islamic Sukuk		300,000,000	300,000,000
Property and equipment	7	16,920,623,412	14,773,148,689
Total non-current assets		**17,383,747,860**	**15,238,502,125**
Total assets		**22,788,262,028**	**20,557,929,072**
Liabilities and equity			
Liabilities			
Current liabilities			
Current portion of long-term loans	11	96,039,119	96,039,119
Accounts payable		2,169,696,176	1,839,938,621
Accruals and other liabilities		2,351,535,085	2,003,645,400
Zakat and income tax payable		100,803,292	147,845,521
Current portion of lease liabilities		94,762,802	74,337,595
Total current liabilities		**4,812,836,474**	**4,161,806,256**
Non-current liabilities			
Long-term loans	11	8,543,047,275	7,661,931,031
Government grant		45,004,798	49,039,737
Lease liabilities		355,377,852	333,161,823
Employees' end-of-service benefits		852,610,257	739,342,128
Total non-current liabilities		**9,796,040,182**	**8,783,474,719**
Total liabilities		**14,608,876,656**	**12,945,280,975**
Equity			
Issued and paid-up share capital		3,500,000,000	3,500,000,000
Retained earnings		4,184,353,523	3,675,142,519
Equity attributable to equity holders of the parent Company		**7,684,353,523**	**7,175,142,519**
Non-controlling interests		495,031,849	437,505,578
Total equity		**8,179,385,372**	**7,612,648,097**
Total liabilities and equity		**22,788,262,028**	**20,557,929,072**

The accompanying notes 1 to 15 form an integral part of these condensed consolidated interim financial statements.

APPROVED BY:	APPROVED BY:	APPROVED BY:
FAISAL AL NASSAR	FAISAL AL NASSAR	DR. SULAIMAN AL HABIB
CFO	CEO	CHAIRMAN

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Condensed consolidated interim statement of profit or loss
For the three month and nine month periods ended 30 September 2025

	Notes	For the three month period ended		For the nine month period ended	
		30 September 2025	30 September 2024	30 September 2025	30 September 2024
		⃁	⃁	⃁	⃁
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Revenue		3,463,343,595	2,976,560,552	10,005,452,321	8,071,586,241
Cost of revenue		(2,413,413,649)	(1,984,464,488)	(6,861,228,203)	(5,324,132,984)
Gross profit		**1,049,929,946**	**992,096,064**	**3,144,224,118**	**2,747,453,257**
Sales and marketing expenses		(96,247,704)	(121,306,486)	(351,058,453)	(341,158,810)
General and administrative expenses		(287,972,371)	(246,407,254)	(856,661,351)	(674,165,229)
Operating profit		**665,709,871**	**624,382,324**	**1,936,504,314**	**1,732,129,218**
Share of income of associates		2,745,929	5,075,311	10,609,512	14,658,126
Finance costs		(85,951,290)	(50,890,019)	(247,981,049)	(89,615,104)
Other income		52,497,234	35,335,055	141,113,181	117,508,281
Profit before zakat and income tax		**635,001,744**	**613,902,671**	**1,840,245,958**	**1,774,680,521**
Zakat and income tax		(9,631,935)	(10,517,459)	(32,741,614)	(38,063,581)
Profit for the period		**625,369,809**	**603,385,212**	**1,807,504,344**	**1,736,616,940**
Profit for the period attributable to:					
Equity holders of the parent Company		602,284,700	595,543,691	1,750,313,782	1,701,517,450
Non-controlling interests		23,085,109	7,841,521	57,190,562	35,099,490
		625,369,809	**603,385,212**	**1,807,504,344**	**1,736,616,940**
Earnings per share:	12				
Basic and diluted earnings per share from profit for the period attributable to equity holders of the parent Company		**1.72**	**1.70**	**5.00**	**4.86**

The accompanying notes 1 to 15 form an integral part of these condensed consolidated interim financial statements.

APPROVED BY:
FAISAL AL NASSAR
CFO

APPROVED BY:
FAISAL AL NASSAR
CEO

APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Condensed consolidated interim statement of comprehensive income
For the three month and nine month periods ended 30 September 2025

	For the three month period ended		For the nine month period ended	
	30 September 2025 ⃁ (Unaudited)	30 September 2024 ⃁ (Unaudited)	30 September 2025 ⃁ (Unaudited)	30 September 2024 ⃁ (Unaudited)
Profit for the period	**625,369,809**	**603,385,212**	**1,807,504,344**	**1,736,616,940**
Other comprehensive income				
Items that will not be reclassified to profit or loss in subsequent periods:				
Remeasurement gain (loss) on defined benefit obligations	3,421,908	6,912,520	(1,764,305)	27,907,339
Other comprehensive income (loss) for the period	**3,421,908**	**6,912,520**	**(1,764,305)**	**27,907,339**
Total comprehensive income for the period	**628,791,717**	**610,297,732**	**1,805,740,039**	**1,764,524,279**
Total comprehensive income for the period attributable to:				
Equity holders of the parent Company	605,934,710	600,474,615	1,748,211,004	1,726,628,661
Non-controlling interests	22,857,007	9,823,117	57,529,035	37,895,618
	628,791,717	**610,297,732**	**1,805,740,039**	**1,764,524,279**

The accompanying notes 1 to 15 form an integral part of these condensed consolidated interim financial statements.

APPROVED BY: FAISAL AL NASSAR CFO	APPROVED BY: FAISAL AL NASSAR CEO	APPROVED BY: DR. SULAIMAN AL HABIB CHAIRMAN

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Condensed consolidated interim statement of changes in equity
For the nine month period ended 30 September 2025

	Attributable to equity holders of the parent Company					
	Issued and paid-up share capital ⃁	Statutory reserve ⃁	Retained earnings ⃁	Total ⃁	Non-controlling interests ⃁	Total equity ⃁
As at 1 January 2025	**3,500,000,000**	**-**	**3,675,142,519**	**7,175,142,519**	**437,505,578**	**7,612,648,097**
Profit for the period	-	-	1,750,313,782	1,750,313,782	57,190,562	1,807,504,344
Other comprehensive income (loss)	-	-	(2,102,778)	(2,102,778)	338,473	(1,764,305)
Total comprehensive income	-	-	1,748,211,004	1,748,211,004	57,529,035	1,805,740,039
Changes in non-controlling interests	-	-	-	-	(2,764)	(2,764)
Dividends (note 10)	-	-	(1,239,000,000)	(1,239,000,000)	-	(1,239,000,000)
As at 30 September 2025 (Unaudited)	**3,500,000,000**	**-**	**4,184,353,523**	**7,684,353,523**	**495,031,849**	**8,179,385,372**
As at 1 January 2024	**3,500,000,000**	**1,050,000,000**	**1,935,484,939**	**6,485,484,939**	**280,756,880**	**6,766,241,819**
Profit for the period	-	-	1,701,517,450	1,701,517,450	35,099,490	1,736,616,940
Other comprehensive income	-	-	25,111,211	25,111,211	2,796,128	27,907,339
Total comprehensive income	-	-	1,726,628,661	1,726,628,661	37,895,618	1,764,524,279
Transfer from statutory reserve	-	(1,050,000,000)	1,050,000,000	-	-	-
Increase in capital of partially owned subsidiary	-	-	-	-	101,788,000	101,788,000
Dividends (note 10)	-	-	(1,221,500,000)	(1,221,500,000)	-	(1,221,500,000)
As at 30 September 2024 (Unaudited)	**3,500,000,000**	**-**	**3,490,613,600**	**6,990,613,600**	**420,440,498**	**7,411,054,098**

The accompanying notes 1 to 15 form an integral part of these condensed consolidated interim financial statements.

APPROVED BY:	APPROVED BY:	APPROVED BY:
FAISAL AL NASSAR	FAISAL AL NASSAR	DR. SULAIMAN AL HABIB
CFO	CEO	CHAIRMAN

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Condensed consolidated interim statement of cash flows
For the nine month period ended 30 September 2025

	2025 ⃁ (Unaudited)	2024 ⃁ (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before zakat and income tax	**1,840,245,958**	**1,774,680,521**
Adjustments for non-cash items:		
Depreciation	486,449,145	287,340,806
Share of income of associates	(10,609,512)	(14,658,126)
Provisions	131,928,166	192,127,594
Finance costs	247,981,049	89,615,104
Employees' end-of-service benefits	142,736,858	120,948,643
	2,838,731,664	**2,450,054,542**
Working capital changes:		
Accounts receivable	(655,776,917)	(718,817,276)
Inventories	(222,539,625)	(235,332,567)
Prepayments and other assets	(157,365,572)	(174,521,797)
Accounts payable	329,757,555	462,410,208
Accruals and other liabilities	343,211,624	200,278,018
Cash generated from operations activities	**2,476,018,729**	**1,984,071,128**
Zakat and income tax paid	(79,783,843)	(72,403,704)
Employees' end-of-service benefits paid	(31,233,034)	(32,010,371)
Net cash from operating activities	**2,365,001,852**	**1,879,657,053**
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property and equipment	(2,470,472,929)	(2,880,122,855)
Investment in associates and others	(3,300,000)	(6,443,812)
Dividends from associates	16,138,500	8,750,000
Net cash used in investing activities	**(2,457,634,429)**	**(2,877,816,667)**
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from long-term loans	1,025,328,054	2,162,030,001
Repayment of long-term loans	(148,098,363)	(148,098,363)
Lease liabilities paid	(81,577,512)	(50,896,031)
Finance costs paid	(243,451,374)	(89,644,769)
Non-controlling interest	(2,764)	101,788,000
Dividends paid	(1,239,000,000)	(1,221,500,000)
Net cash (used in) / generated from financing activities	**(686,801,959)**	**753,678,838**
Net decrease in cash and cash equivalents	(779,434,536)	(244,480,776)
Cash and cash equivalents at the beginning of the period	2,890,702,697	2,620,380,482
Cash and cash equivalents at the end of the period	**2,111,268,161**	**2,375,899,706**
Non-cash transactions:		
Recognition of right-of-use assets and lease liabilities	124,218,748	140,131,225
Transfer from prepayments and other assets to property and equipment	39,978,296	-

The accompanying notes 1 to 15 form an integral part of these condensed consolidated interim financial statements.

APPROVED BY: FAISAL AL NASSAR CFO	APPROVED BY: FAISAL AL NASSAR CEO	APPROVED BY: DR. SULAIMAN AL HABIB CHAIRMAN

1 Corporate information and activities

Dr. Sulaiman Al Habib Medical Services Group Company (the "Company") (a Saudi Listed Joint Stock Company) is registered in Riyadh, under commercial registration number 1010118330 dated 11 Jumada al-thani 1414H (corresponding to 25 November 1993). The registered office is located at Olaya District, P.O. Box 301578, Riyadh 11372, Kingdom of Saudi Arabia (the" KSA"), and the Company was listed on the Saudi Stock Exchange (Tadawul) on 22 Rajab 1441H (corresponding to 17 March 2020).

The activities of the Company and its subsidiaries (collectively referred to as "the Group") are to provide private health services and ancillary services for its operations in KSA and the region through the establishment, management, and operation of hospitals, general and specialized medical complexes, day surgery centers, pharmaceutical facilities, and other ancillary areas which include providing services of home health care, specialized medical laboratories, technology services & information systems, providing facility maintenance services, Tele-medicine services, revenue cycle management services, medical equipment maintenance services, and real estate activity.

The Company has a branch located in Riyadh, KSA, "Branch of Dr. Sulaiman Al Habib Medical Services Group Company" ("the Branch") under commercial registration number 1010357146 dated 24 Muharram 1434H (corresponding to 8 December 2012). The Branch is engaged in the activities of retail sales of medical devices, equipment, and supplies, as well as operating pharmaceutical warehouses and general warehouses that store a range of goods.

The number of shares is (350,000,000) and the share value is ⃁ 10.

The condensed consolidated interim financial statements include the financial information of the branch mentioned above and subsidiaries mentioned in note 3.

2 Basis of preparation

2.1 Statement of compliance

These condensed consolidated interim financial statements as at and for the three-month and nine-month periods ended 30 September 2025 have been prepared in accordance with International Accounting Standard 34 – "Interim Financial Reporting" (IAS 34) as endorsed in the Kingdom of Saudi Arabia ("KSA") and other standards and pronouncements issued by the Saudi Organization for Chartered and Professional Accountants ("SOCPA") (collectively referred to as "IAS-34 as endorsed in KSA").

The condensed consolidated interim financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should therefore be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2024.
The condensed consolidated interim financial statements are considered an integral part of the whole fiscal year, however, the results of operations for the interim period may not be a fair indication of the results of the full year operations.

2.2 Basis of measurement

These condensed consolidated interim financial statements are prepared on a historical cost basis except for employees' end of service benefits are recognized at the present value of future obligations using the Projected Unit Credit Method.

2.3 Functional and presentation currency

The condensed consolidated interim financial statements are presented in Saudi Riyals, which is the functional, and presentation currency of the Group and all values are rounded to the nearest one Saudi Riyal, except when otherwise indicated.

2.4 Use of judgement and estimates

In preparing these condensed consolidated interim financial statements, management has made judgments and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual Consolidated Financial Statements.

3 Basis of consolidation

These condensed consolidated interim financial statements comprise the financial statements of the Company and its following subsidiaries (collectively referred to as "the Group"), mainly domiciled in the Kingdom of Saudi Arabia ("KSA") and United Arab Emirates ("UAE") as at 30 September 2025 and 31 December 2024:

			Ownership %	
	Country of incorporation and business	**Activities / Services**	**30 September 2025**	**31 December 2024**
Sehat Al Olaya Medical Complex Company	KSA	Hospital	100%	100%
Asharq Alawsat Pharmacies Company	KSA	Pharmacy	100%	100%
Dr. Sulaiman Al Habib Hospital FZ – LLC	UAE	Hospital	100%	100%
Buraidah Al Takhassusi Hospital for Healthcare Company	KSA	Hospital	100%	100%
Al Rayan Hospital for Healthcare Company	KSA	Hospital	100%	100%
Home Healthcare Company	KSA	Home Healthcare	100%	100%
Al Gharb Al Takhassusi Hospital for Healthcare Company	KSA	Hospital	100%	100%
Al Mokhtabarat Diagnostic Medical Company	KSA	Laboratory	100%	100%
Sehat Al Suwaidi Medical Company	KSA	Hospital	100%	100%
Hulool Al Sahaba for IT & Communication Company	KSA	IT Support	100%	100%
Rawabet Medical Company	KSA	Medical and Telemedicine	100%	100%
Sehat Al Sharq Medical Limited Company	KSA	Hospital	50%	50%
Al Wosta Medical Limited Company	KSA	Hospital	50%	50%
Gharb Jeddah Hospital Company	KSA	Hospital	50%	50%
Shamal Al Riyadh for Healthcare Company	KSA	Hospital	100%	100%
Al Muhammadiyah Hospital for Healthcare Company	KSA	Hospital	100%	100%
Taswyat Administrative Company	KSA	Revenue cycle management	100%	100%
Al Marakez Al Awwalyah for Healthcare Company	KSA	Primary Healthcare centers	100%	100%
Wrass Real Estate Company	KSA	Real Estate	100%	100%
Flow Medical Company	KSA	Medical equipment maintenance	100%	100%
Sehat Al Kharj for Healthcare Company	KSA	Hospital	100%	100%
Bawabat Al Gharb for Healthcare Company	KSA	Hospital	100%	100%
Bawabat Al Shamal for Healthcare Company	KSA	Hospital	100%	100%
Sehat Al Hamra for Healthcare Company	KSA	Hospital	100%	100%
Wrass for Operation and Maintenance Company	KSA	Anciliary	100%	100%
Dr. Sulaiman Al Habib for Education Company	KSA	Higher Education	100%	100%
Bawabat Al Sharq for Healthcare Company	KSA	Hospital	100%	100%
Sehat Al Sahel Company *	KSA	Hospital	100%	-

* *During the period, the Group established new subsidiary, namely "Sehat Al Sahel Company".*

Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has:

- Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee);
- Exposure, or rights, to variable returns from its involvement with the investee;
- The ability to use its power over the investee to affect its returns.

Generally, there is a presumption that a majority of voting rights results in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- The contractual arrangement(s) with the other vote holders of the investee;
- Rights arising from other contractual arrangements;
- The Group's voting rights and potential voting rights.

3 Basis of consolidation (continued)

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income (OCI) are attributed to the equity holders of the parent of the Group and non-controlling interest, even if this results in the non-controlling interest having a deficit balance.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with the Group's accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it:

- Derecognizes the assets and liabilities of the subsidiary;
- Derecognizes the carrying amount of any non-controlling interest;
- Recognizes the fair value of the consideration received;
- Recognizes the fair value of any investment retained;
- Recognizes any surplus or deficit in profit or loss;
- Reclassifies the parent's share of components previously recognized in other comprehensive income to profit or loss or retained earnings, as appropriate, as would be required if the Group had directly disposed of the related assets or liabilities.

4 Consistent application of accounting policies

The accounting policies adopted in the preparation of the condensed consolidated interim financial statements are consistent with those followed in preparing the Group's annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of new standards effective as of 1 January 2025. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

5 New standards effective as of 1 January 2025

Lack of exchangeability - Amendments to IAS 21

The amendment prescribes accounting when there is a lack of exchangeability in the currency of an entity when it has a transaction or an operation in a foreign currency. A currency is exchangeable when there is an ability to obtain the other currency (with a normal administrative delay), and the transaction would take place through a market or exchange mechanism that creates enforceable rights and obligations. As there are no major transactions or the operations of the Group where the entity is subject to lack of exchangeability, this amendment does not have any material impact on the Group's condensed consolidated interim financial statements.

5. 1 New standards and interpretations not yet adopted by the Group

Certain new accounting standards and amendments to accounting standards have been published that are not mandatory for 30 September 2025 reporting periods and have not been early adopted by the Group.

- Amendments to the Classification and Measurement of Financial Instruments - Amendments to IFRS 9 and IFRS 7 (issued on 30 May 2024 and effective for annual periods beginning on or after 1 January 2026).

- IFRS 18 Presentation and Disclosure in Financial Statements (Issued on 9 April 2024 and effective for annual periods beginning on or after 1 January 2027).

- IFRS 19 Subsidiaries without Public Accountability: Disclosures (Issued on 9 May 2024 and effective for annual periods beginning on or after 1 January 2027).

6 Segment Information

Operating segments is determined based on the Group's internal reporting to the Chief Operating Decision Maker ("CODM").

The CODM uses underlying measures which are reviewed at monthly Executive Committee and Performance meetings. Revenue and segment profitability are consistently applied across the Group as the key measures of segment results for the reporting period.

The identified key segments are Hospitals / Healthcare Facilities, Pharmacies and Solutions / Others (which includes IT support services, laboratory services, home healthcare services, medical equipments maintenance, revenue cycle management and real estate). The segment results for the nine month period ended 30 September 2025 and the reconciliation of the segment measures to the respective statutory items included in the condensed consolidated interim financial statements are as follows:

⃁ Million	Hospitals/ Healthcare Facilities	Pharmacies	Solutions / Others	Total
For the nine month period ended 30 September 2025 (Unaudited)				
Revenue	7,772	2,067	166	10,005
Gross profit	2,441	619	84	3,144
As at 30 September 2025 (Unaudited)				
Total assets	19,139	819	2,830	22,788
Total liabilities	10,267	873	3,469	14,609
For the nine month period ended 30 September 2024 (Unaudited)				
Revenue	6,158	1,693	221	8,072
Gross profit	2,200	504	43	2,747
As at 31 December 2024 (audited)				
Total assets	16,131	638	3,789	20,558
Total liabilities	9,797	799	2,349	12,945

7 Property and equipment

	As at 30 September 2025 ⃁ (Unaudited)	As at 31 December 2024 ⃁ (Audited)
Property and equipment	16,412,841,299	14,318,897,769
Right-of-use assets *	507,782,113	454,250,920
	16,920,623,412	**14,773,148,689**

* Right-of-use assets mainly pertains to lease of lands and accommodation for the Group employees.

8 Related party disclosures

Related parties represent shareholders, Directors and key management personnel of the Group, and entities controlled, jointly controlled or significantly influenced by such parties. Pricing policies and terms of these transactions are approved by the Group's management.

Related party transactions

Significant transactions with related parties in the ordinary course of business which are included in the condensed consolidated interim financial statements are summarized as follows:

Related party	Nature of transaction	For the nine month period ended 30 September 2025 ⃁ (Unaudited)	30 September 2024 ⃁ (Unaudited)
Board of Directors	Purchases and services	71,731,483	29,470,875
Affiliates Parties	Purchases and services	109,368,877	69,589,723
Associates Parties	Purchases and services	10,593,313	10,017,536
Affiliates Parties	Capital work-in-progress	9,250,336	65,135,039
Associates Parties	Revenue	64,152,224	51,611,600

Compensation of key management personnel of the Group

Key management personnel of the Group comprise of the Board of Directors and key members of management having authority and responsibility for planning, directing and controlling the activities of the Group.

	For the nine month period ended 30 September 2025 ⃁ (Unaudited)	30 September 2024 ⃁ (Unaudited)
Short-term employee benefits	11,240,000	10,710,000
Board of Directors and its committees remuneration	2,235,000	2,201,500
Post-employment and medical benefits	936,667	892,500
Total compensation paid to key management personnel	**14,411,667**	**13,804,000**

9 Zakat and income tax

9.1 Zakat

The following table summarizes the zakat status for the Group and it's subsidiaries on reporting date:

Zakat Status	Company ownership %	Zakat return filed up to	Zakat Certificate received up to	Final Zakat assessment received up to
Consolidated zakat returns for the Company and its subsidiaries	100	2024	2024	2023
Sehat Al Sharq Medical Limited Company	50	2024	2024	2020
Gharb Jeddah Hospital Company	50	2024	2024	2022
Al Wosta Medical Limited Company	50	2024	2024	2022
Asharq Alawsat Pharmacies Company	100	2024	2024	2023

9 Zakat and income tax (continued)

9.2 Income Tax

UAE Corporate Income Tax Law On 9 December 2022, the UAE Ministry of Finance released Federal Decree-Law No. 47 of 2022 on the Taxation of Corporations and Businesses (Corporate Tax Law or the Law) to enact a Federal corporate tax (CT) regime in the UAE. The CT regime is effective for accounting periods beginning on or after 1 June 2023. The Group subsidiary in Dubai is subject to the provisions of the UAE CT Law with effect from 1 January 2024.

10 Dividends

During the period ended 30 September 2025, the Board of Directors resolved to distribute interim dividends of ⃁ 3.54 per share totaling to ⃁ 1,239,000,000 (30 September 2024: interim dividends of ⃁ 3.49 per share making a total of ⃁ 1,221,500,000) as follows:

- On 15 February 2025, the Board of Directors resolved to distribute interim dividends of ⃁ 430,500,000 at ⃁ 1.23 per share (representing 12.3% of the nominal value of the share) for the 4th quarter of 2024, based on the authorization to distribute interim dividends to the shareholders, quarterly or semi-annually, for the fiscal year 2024 which was granted to the Board of Directors by the Extraordinary General Assembly which was held on Tuesday 6 Dhu al-Qi'dah 1445H (corresponding to 14 May 2024).

- On 3 May 2025, the Board of Directors resolved to distribute interim dividends of ⃁ 392,000,000 at ⃁ 1.12 per share (representing 11.2% of the nominal value of the share) for the 1st quarter of 2025, based on the authorization to distribute interim dividends to the shareholders, quarterly or semi-annually, for the fiscal year 2025 which was granted to the Board of Directors by the Ordinary General Assembly which was held on Wednesday 3 Jamada Al-Thani 1446H (corresponding to 4 December 2024)

- On 26 July 2025, the Board of Directors resolved to distribute interim dividends of ⃁ 416,500,000 at ⃁ 1.19 per share (representing 11.9% of the nominal value of the share) for the 2nd quarter of 2025, based on the authorization to distribute interim dividends to the shareholders, quarterly or semi-annually, for the fiscal year 2025 which was granted to the Board of Directors by the Ordinary General Assembly which was held on Sunday 6 Dhu al-Qi'dah 1446H (corresponding to 4 May 2025)

11 Long-term loans

	As at 30 September 2025 ⃁ (Unaudited)	**As at 31 December 2024 ⃁ (Audited)**
Current portion of long-term loans:		
Loans from local banks (i)	61,835,713	61,835,713
Loans from Ministry of Finance (ii)	34,203,406	34,203,406
	96,039,119	**96,039,119**
Non-current portion of long-term loans:		
Loans from local banks (i)	8,277,183,551	7,375,526,921
Loans from Ministry of Finance (ii)	265,863,724	286,404,110
	8,543,047,275	**7,661,931,031**

i) Loans from local banks

The Group obtained Islamic facilities in the form of long-term loans (Murabaha / Tawarruq) from local banks. These facilities are subject to commission rates based on Saudi Arabia Interbank Offered Rate "SIBOR" plus an agreed margin. The facilities are secured by corporate promissory notes.

11 Long-term loans (continued)

ii) Loans from Ministry of Finance (MoF)

The Group's long-term financing includes MoF non-interest bearing loans to finance the capital expenditures related to the Company and its subsidiaries. The loan repayment installments are settled on equal yearly installments. Certain assets are pledged against the loans obtained from the MoF.

12 Earnings per share

Basic and diluted earnings per share ("EPS") is calculated by dividing the profit for the period attributable to ordinary equity holders by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per share is the same as the regular or basic earnings per share as the Group does not have any convertible securities or diluted instruments to exercise.

The following table reflects the profit for the period attributable to equity holders of the parent Company and share data used in the basic and diluted EPS computations:

	For the three month period ended		For the nine month period ended	
	30 September 2025 ⃁ (Unaudited)	30 September 2024 ⃁ (Unaudited)	30 September 2025 ⃁ (Unaudited)	30 September 2024 ⃁ (Unaudited)
Profit for the period attributable to equity holders of the parent Company	602,284,700	595,543,691	1,750,313,782	1,701,517,450
Weighted average number of ordinary shares	350,000,000	350,000,000	350,000,000	350,000,000
Basic and diluted earnings per share from profit for the period attributable to equity holders of the parent Company	1.72	1.70	5.00	4.86

Note; There were no potential ordinary shares outstanding during the period; therefore, basic and diluted earnings per share are identical.

13 Fair values

Financial instruments comprise financial assets and financial liabilities. Financial assets consist of cash and cash equivalents and accounts receivable, Investments in equity instruments – Islamic Sukuk, contract assets and others. Financial liabilities consist of long-term loans, accounts payable, lease liabilities, accruals and other liabilities.

The fair value of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The fair values of financial instruments are not materially different from their carrying values at reporting date.

14 Subsequent events

Management has evaluated events occurring after the reporting period up to the date of approval of the condensed consolidated interim financial statements and concluded that there are no events that require adjustment to or disclosure in the condensed consolidated interim financial statements.

15 Approval of the condensed consolidated interim financial statements

These condensed consolidated interim financial statements were approved for issuance by the Board of Directors on 3 Jumada al-Awwal 1447 H (corresponding to 25 October 2025).